ANIP · NASDAQ
ANI Pharmaceuticals (ANIP) Stock Price & Fundamentals
ANI Pharmaceuticals (ANIP) closed at $991.46 on Oct 9, 2026, down 0.78% from the previous close of $999.29.
Share price, past year
1Y +24.94%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $991.46 |
| Sep 30, 2026 | $974.08 |
| Aug 31, 2026 | $1,008.43 |
| Jul 31, 2026 | $991.61 |
| Jun 30, 2026 | $958.91 |
| May 29, 2026 | $866.34 |
| Apr 30, 2026 | $842.64 |
| Mar 31, 2026 | $901.71 |
| Feb 27, 2026 | $893.89 |
| Jan 30, 2026 | $909.98 |
| Dec 31, 2025 | $876.55 |
| Nov 28, 2025 | $908.65 |
| Oct 31, 2025 | $874.46 |
Key statistics
- Market cap
- $22.30B
- P/E (TTM)
- 215.5
- EPS (TTM)
- $4.60
- Revenue (TTM)
- $978.38M
- Net income (TTM)
- $108.31M
- Shares outstanding
- 22.5M
- Dividend yield
- —
- 52-week range
- $793.52 – $1,022.99
ANI Pharmaceuticals's market cap is $22.30B, based on a share price of $991.46 and 22.5M shares outstanding as of Dec 31, 2025.
Financials
ANI Pharmaceuticals reported revenue of $883.37M for fiscal 2025, up 43.78% from fiscal 2024.
ANI Pharmaceuticals earned net income of $78.34M in fiscal 2025, a net margin of 8.9%.
Fiscal 2025 revenue was the highest in the 10 years shown.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $883.37M | +43.8% | $78.34M | 8.9% | $3.32 | $171.39M |
| FY2024ended Dec 31, 2024 | $614.38M | +26.2% | −$18.52M | −3.0% | −$1.04 | $47.78M |
| FY2023ended Dec 31, 2023 | $486.82M | +53.9% | $18.78M | 3.9% | $0.85 | $110.09M |
| FY2022ended Dec 31, 2022 | $316.39M | +46.4% | −$47.90M | −15.1% | −$3.05 | −$40.08M |
| FY2021ended Dec 31, 2021 | $216.14M | +3.7% | −$42.60M | −19.7% | −$3.40 | $765.00K |
| FY2020ended Dec 31, 2020 | $208.48M | +0.9% | −$22.55M | −10.8% | −$1.88 | $9.13M |
| FY2019ended Dec 31, 2019 | $206.55M | +2.5% | $6.09M | 3.0% | $0.50 | $39.00M |
| FY2018ended Dec 31, 2018 | $201.58M | +14.0% | $15.49M | 7.7% | $1.30 | $61.33M |
| FY2017ended Dec 31, 2017 | $176.84M | +37.5% | −$1.08M | −0.6% | −$0.09 | $29.05M |
| FY2016ended Dec 31, 2016 | $128.62M | — | $3.93M | 3.1% | $0.34 | $22.91M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $266.04M | $24.71M | $1.05 |
| Q1 FY2026ended Mar 31, 2026 | $237.46M | $29.49M | $1.28 |
| Q4 FY2025ended Dec 31, 2025 | $247.06M | $27.49M | $1.14 |
| Q3 FY2025ended Sep 30, 2025 | $227.81M | $26.62M | $1.13 |
| Q2 FY2025ended Jun 30, 2025 | $211.37M | $8.55M | $0.36 |
| Q1 FY2025ended Mar 31, 2025 | $197.12M | $15.68M | $0.69 |
| Q4 FY2024ended Dec 31, 2024 | $190.57M | −$10.28M | −$0.45 |
| Q3 FY2024ended Sep 30, 2024 | $148.33M | −$24.17M | −$1.27 |
Company profile
- Name
- ANI Pharmaceuticals, Inc.
- Ticker
- ANIP
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 104 Carnegie Center Drive Suite 300, Princeton, NJ 08540
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001023024
Recent SEC filings
- Aug 24, 2026
- Aug 7, 2026
- Aug 7, 2026
- May 21, 2026
- May 13, 2026
- May 8, 2026
- May 8, 2026
- Apr 7, 2026
Frequently asked questions
What is ANI Pharmaceuticals's stock price?
ANI Pharmaceuticals (ANIP) closed at $991.46 on Oct 9, 2026, down 0.78% from the previous close of $999.29.
What is ANI Pharmaceuticals's market cap?
ANI Pharmaceuticals's market cap is $22.30B, based on a share price of $991.46 and 22.5M shares outstanding as of Dec 31, 2025.
How much revenue does ANI Pharmaceuticals make?
ANI Pharmaceuticals reported revenue of $883.37M for fiscal 2025, up 43.78% from fiscal 2024.
What is ANIP's P/E ratio?
ANI Pharmaceuticals's price-to-earnings ratio is 215.5, based on trailing twelve-month diluted EPS of $4.60.
Does ANI Pharmaceuticals pay a dividend?
ANI Pharmaceuticals's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from ANI Pharmaceuticals, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures